FDA Approved Fayuvi for Sanfilippo Syndrome Type A

The treatment aims to address the underlying genetic cause of the rare neurodegenerative condition in children.

Updated on Sept. 18, 2026 in Allergies

Isometric editorial illustration of a geometric adeno-associated virus capsid particle, representing genetic therapy for Sanfilippo syndrome. — The FDA approved Fayuvi, a gene therapy for children with Sanfilippo syndrome type A that targets the underlying genetic cause of the condition. AI Illustration. Upload story photo >

The FDA has granted approval for Fayuvi as a treatment for children diagnosed with Sanfilippo syndrome type A. The therapy serves patients suffering from this rare genetic condition that typically manifests in early childhood.

Why it matters

Patients with Sanfilippo syndrome type A lack the vital sulfamidase enzyme, leading to a toxic buildup of heparan sulfate in the body and brain. This approval offers a new intervention for a condition that severely limits life expectancy to between 11 and 19 years.

The clinical study evaluated children aged 2 to 5 years, testing a single intravenous dose of Fayuvi. Sanfilippo syndrome occurs in 1 in every 50,000 to 200,000 people, with type A cases representing more than half of that population.

The players

FDA

The FDA is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.

The details

Fayuvi utilizes adeno-associated virus serotype 9 to deliver a functional copy of the SGSH gene to the patient cells. The regimen requires a single intravenous infusion alongside corticosteroid treatment for at least 8 weeks to manage the body's response.

The FDA approved Fayuvi for children with Sanfilippo syndrome type A on September 18, 2026.
Symptoms for type A generally appear in patients aged 1 to 4 years.
The clinical study involved participants aged 2 to 5 years.
Patients require corticosteroid treatment for a minimum of 8 weeks after their infusion.
Life expectancy for patients with type A is typically between 11 and 19 years.

Biotech
Sept. 23
FDA Granted Breakthrough Status to Glycomine Drug
Allergies
Sept. 23
FDA Approved Gene Therapy for Sanfilippo Syndrome
Healthcare
Sept. 21
Congress Will Consider Prescription Drug Fee Renewal

The Big Picture

This approval follows the established framework of the FDA Orphan Drug designation program, which prioritizes therapies for rare, life-limiting conditions. The authorization extends the reach of gene therapy interventions into specialized pediatric neurodegenerative care.

Parents and caregivers should consult with medical specialists regarding the potential risks of Fayuvi, which include tumor development and thrombotic microangiopathy. Families must also plan for the required corticosteroid treatment duration to ensure the safety and efficacy of the infusion.

The takeaway

While the approval of Fayuvi provides a critical new option for addressing the genetic roots of type A, the therapy carries specific risks that require careful clinical monitoring. Families are encouraged to discuss these medical trade-offs with their primary care and specialist teams.